Optimizing the Concentration and Bolus of a Drug Delivered by Continuous Infusion
Summary We consider treatment regimes in which an agent is administered continuously at a specified concentration until either a response is achieved or a predetermined maximum infusion time is reached. Response is an event defined to characterize therapeutic
efficacy. A portion of the maximum planned total amount administered is given as an initial bolus. For such regimes, the amount of the agent received by the patient depends on the time to response. An additional complication when response is evaluated periodically rather than continuously
is that the response time is interval censored. We address the problem of designing a clinical trial in which such response time data and a binary indicator of toxicity are used together to jointly optimize the concentration and the size of the bolus. We propose a sequentially adaptive Bayesian
design that chooses the optimal treatment for successive patients by maximizing the posterior mean utility of the joint efficacy‐toxicity outcome. The methodology is illustrated by a trial in which tissue plasminogen activator is infused intraarterially as rapid treatment for acute
No Supplementary Data
No Article Media
Document Type: Research Article
Department of Biostatistics, M.D. Anderson Cancer Center, Houston, Texas 77030, U.S.A.
Department of Population Health, Medical College of Wisconsin, Milwaukee, Wisconsin 53226, U.S.A.
Department of Neurology, Neurosurgery and Radiology, Medical College of Wisconsin, Milwaukee, Wisconsin 53226, U.S.A.
Publication date: 2011-12-01